These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37783100)

  • 21. A comprehensive look of poly(ADP-ribose) polymerase inhibition strategies and future directions for cancer therapy.
    Kumar C; Rani N; Velan Lakshmi PT; Arunachalam A
    Future Med Chem; 2017 Jan; 9(1):37-60. PubMed ID: 27995810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of novel PARP-1 inhibitors: Drug design, synthesis and biological evaluation.
    Xie Z; Zhou Y; Zhao W; Jiao H; Chen Y; Yang Y; Li Z
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4557-61. PubMed ID: 26342868
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery and structure-activity relationships of modified salicylanilides as cell permeable inhibitors of poly(ADP-ribose) glycohydrolase (PARG).
    Steffen JD; Coyle DL; Damodaran K; Beroza P; Jacobson MK
    J Med Chem; 2011 Aug; 54(15):5403-13. PubMed ID: 21692479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
    Cerrato A; Morra F; Celetti A
    J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Active Targeted Nanoparticles for Delivery of Poly(ADP-ribose) Polymerase (PARP) Inhibitors: A Preliminary Review.
    Sargazi S; Mukhtar M; Rahdar A; Barani M; Pandey S; Díez-Pascual AM
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of 2-(1-(3-(4-Chloroxyphenyl)-3-oxo- propyl)pyrrolidine-3-yl)-1
    Min R; Wu W; Wang M; Tang L; Chen D; Zhao H; Zhang C; Jiang Y
    Molecules; 2019 May; 24(10):. PubMed ID: 31108884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contrasting sirtuin and poly(ADP-ribose)polymerase activities of selected 2,4,6-trisubstituted benzimidazoles.
    Yeong KY; Tan SC; Mai CW; Leong CO; Chung FF; Lee YK; Chee CF; Abdul Rahman N
    Chem Biol Drug Des; 2018 Jan; 91(1):213-219. PubMed ID: 28719017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis and anticancer activities of novel dual poly(ADP-ribose) polymerase-1/histone deacetylase-1 inhibitors.
    Tian Y; Xie Z; Liao C
    Bioorg Med Chem Lett; 2020 Apr; 30(8):127036. PubMed ID: 32088129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PARP inhibitors for cancer therapy.
    Curtin NJ
    Expert Rev Mol Med; 2005 Mar; 7(4):1-20. PubMed ID: 15836799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of Quinazoline-2,4(1
    Zhou J; Ji M; Wang X; Zhao H; Cao R; Jin J; Li Y; Chen X; Sheng L; Chen X; Xu B
    J Med Chem; 2021 Nov; 64(22):16711-16730. PubMed ID: 34748333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and synthesis of benzodiazepines as brain penetrating PARP-1 inhibitors.
    Yu J; Gou W; Shang H; Cui Y; Sun X; Luo L; Hou W; Sun T; Li Y
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):952-972. PubMed ID: 35317687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis and biological activity of novel molecules designed to target PARP and DNA.
    Goodfellow E; Senhaji Mouhri Z; Williams C; Jean-Claude BJ
    Bioorg Med Chem Lett; 2017 Feb; 27(3):688-694. PubMed ID: 28003142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
    Li Y; Liu CF; Rao GW
    Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in cancer therapy using PARP inhibitors.
    Kaur SD; Chellappan DK; Aljabali AA; Tambuwala M; Dua K; Kapoor DN
    Med Oncol; 2022 Sep; 39(12):241. PubMed ID: 36180646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Computational investigation of FDA approved drugs as selective PARP-1 inhibitors by targeting BRCT domain for cancer therapy.
    Kumar C; Lakshmi PTV; Arunachalam A
    J Mol Graph Model; 2021 Nov; 108():107919. PubMed ID: 34304979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enabling drug discovery for the PARP protein family through the detection of mono-ADP-ribosylation.
    Lu AZ; Abo R; Ren Y; Gui B; Mo JR; Blackwell D; Wigle T; Keilhack H; Niepel M
    Biochem Pharmacol; 2019 Sep; 167():97-106. PubMed ID: 31075269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking and Biological Evaluation for Identification of Potential Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors.
    Zhou Y; Tang S; Chen T; Niu MM
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31766720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors as a Promising Strategy for Cancer Therapy.
    Wang J; Li H; He G; Chu Z; Peng K; Ge Y; Zhu Q; Xu Y
    J Med Chem; 2020 Jan; 63(1):122-139. PubMed ID: 31846325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Review on DNA Repair Inhibition by PARP Inhibitors in Cancer Therapy.
    Shah AP; Patel CN; Sureja DK; Sanghavi KP
    Folia Med (Plovdiv); 2018 Mar; 60(1):39-47. PubMed ID: 29668451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.